Disc Medicine, Inc.

Foresite Capital Acquisition Corp. IV, which traded under the ticker FSDC and was sponsored by Foresite Capital Management, completed its business combination with Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on the treatment of serious hematologic diseases. The SPAC filed an 8-K with the SEC on June 9, 2023, accession number 0001193125-23-164532, reflecting activity tied to the closing of that merger. FSDC conducted its IPO in 2021 and targeted the healthcare and biotechnology sector, consistent with Foresite Capital's life-sciences investment focus. The combined company, Disc Medicine, operates in the rare blood disorder space. Sign up at SpacDesk for full filing history, deal timelines, and sponsor data on this transaction.